ArticlePulmonary therapy2026
Symptomatic Sarcoidosis Treated with Acthar
Article in Pulmonary therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acthar Gel treatment in patients with rheumatoid arthritis, systemic lupus erythematosus, or dermatomyositis/polymyositis: analysis of physician-reported charts.Journal of comparative effectiveness research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionReal-world data on evolving treatment patterns of Acthar Gel, a Food and Drug Administration-approved therapy for patients with symptomatic sarcoidosis, have remained limited. This study described the characteristics of patients with symptomatic sarcoidosis treated with Acthar Gel, medication utilization patterns, and physicians' assessments of the effects of Acthar Gel on patients' health status.
methodsA prospectively designed medical chart review study with a predefined protocol and analysis plan was conducted in November 2024, with data abstracted from patient records between April 2022 and November 2024. Eligible patients were aged ≥ 18 years, had symptomatic sarcoidosis, and had received Acthar Gel within ≤ 24 months.
resultsOn average, patients with symptomatic sarcoidosis were 47 years old; most were men (56%, 22/39) and African American (46%, 18/39). Common comorbidities included chronic joint disease, hypertension, and arthritis/osteoarthritis. Before receiving Acthar Gel, physicians reported that 56% (22/39) of patients had a fair-to-poor health status (average rating 3.4/5, where 1 = excellent and 5 = poor). Frequent symptoms were fatigue, joint pain, and muscle aches or weakness. Before initiating Acthar Gel, most patients with symptomatic sarcoidosis had previously received treatment with corticosteroids (82%, 32/39), immunosuppressive drugs (51%, 20/39), and biologic disease-modifying antirheumatic drugs (51%, 20/39). Based on physician assessment, 92% (36/39) of patients experienced improved health after Acthar Gel treatment. Improvements included reduced overall symptoms (69%, 25/36), improved physical function (47%, 17/36), decreased pain (44%, 16/36), improved fatigue (36%, 13/36), reduced corticosteroid use (33%, 12/36), improved lung functioning (25%, 9/36), and improved strength (22%, 8/36).
conclusionsBased on this chart review, Acthar Gel may represent a potential treatment option for selected patients with symptomatic sarcoidosis. In this study, among patients with symptomatic sarcoidosis treated with Acthar Gel, physicians documented reduced overall symptoms, improved physical function, decreased pain, improved fatigue, reduced corticosteroid use, improved lung functioning, and improved strength using prespecified assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.